A New Aspirin (NOSH-Aspirin) can Prevent Several Cancers sans Its Side Effects
Blog :Clinician On Net
Date: 3/9/2012 2:25:00 PM
There has been much talk about aspirin in recent days. Once aspirin as a part of APC (Aspirin, Phenacetin and Caffeine), a panacea for headache and flu was long forgotten for its severe side effects such as gastrointestinal ulceration and bleeding.
But, again it was up for its preventive effect on heart stroke and was used in post-heart stroke patients primarily for prevention of dangerous clot formation. It keeps blood in a more fluid state by preventing action of platelets from wrongful aggregation.
Much work in the recent years have proved that the low cost drug is also helpful in preventing many cancers as well as for early diagnosis of many.
Still, the prescription of the drug is on the basis of weighing the essentiality against possible side effects.
Now, scientists from The City College of New York have developed a new aspirin compound that has great promise to be not only an extremely potent cancer-fighter, but even safer than the classic drug.
the new molecule is a hybrids of aspirin (ASA), bearing both nitric oxide (NO) and hydrogen sulfide (H2S)-releasing moieties, designated as NOSH-Aspirin.
The new aspirin has cancer inhibiting properties on cell lines of adenomatous (colon, pancreatic, lung, prostate), epithelial (breast), and lymphocytic (leukemia) origin.
This compound is also devoid of many cellular toxicity due to presence of nitric oxide and hydrogen sulphide.